Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Teijin: Bonalon to Spur Business in 2nd Half
November 25, 2002
- PRESS SEMINAR
November 25, 2002
- Kyowa Hakko: Drug Sales Down 0.6% to \71.4 Bil.
November 25, 2002
- DIAGNOSTICS NEWS IN BRIEF
November 25, 2002
- Torii: Sales in 1st Half Down 7.9%
November 25, 2002
- New Drug Organization to Properly Conduct Safety Surveillance: Dr Sakaguchi
November 25, 2002
- Nippon Shinyaku: Sales, Profitability Show Signs of Recovery
November 25, 2002
- EAD Director Urges Wholesalers to Eliminate Inappropriate Trade Practices: FJPWA Seminar
November 25, 2002
- Ono: Mainstays Contribute to Sales, Profits Growth
November 25, 2002
- NEW PRODUCTS
November 25, 2002
- Dainippon: Sales Up, Profits Remain at Low Levels
November 25, 2002
- WEBSITE NEWS
November 25, 2002
- Tanabe Seiyaku: Record Profits Despite Lower Sales
November 25, 2002
- BUSINESS NEWS IN BRIEF
November 25, 2002
- Chugai: Net Loss Due to Merger-related Costs
November 25, 2002
- Abbott Japan to Be Formed on Feb. 2003
November 25, 2002
- Daiichi: Sales, Profits Down from Price Cut Impact on Mainstays
November 25, 2002
- Nippon Kayaku to Make Full Use of Own Unique Technology
November 25, 2002
- Shionogi: Contracting Market Hurts Semiannual Sales, Profits
November 25, 2002
- Over 100 Mil. Prescriptions Issued for Pharmacia's Xalatan
November 18, 2002
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…